Clinical Trial Update: Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating MEDI4736 (durvalumab) added to taxane-anthracycline chemotherapy for triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED